Monoclonal antibodies article comments (Chris)
- Condition
- Long COVID
- At worst
- Severe (mostly bedbound)
- Ill for
- 9 months
- Published
- Dec 2025
Summary
Chris is participating in a Vanderbilt clinical trial of baricitinib for long COVID, having started the drug on October 18, 2025. He reported feeling "the best I have since I got Covid," becoming functional though still limited. As of his comment he was experiencing a recent setback triggered by a sore throat infection, suggesting the improvement had not fully held.
What they credit
Credits Biologics & antibodies, JAK inhibitors (Rinvoq, baricitinib), Monoclonal antibodies (casirivimab, Pemgarda).
Similar stories
-
Filgotinib (JAK1 inhibitor) - future of CFS/ME treatment
Took filgotinib 200mg for three days in early 2023, after about three years of suspected ME/CFS that at its worst left him housebound, able to walk ten minutes before needing hours of rest and to sit upright only twenty minutes at a stretch while working…
-
Three clinical trials for Long COVID are testing JAK inhibitors (unnamed)
Credits upadacitinib. An unnamed patient had long COVID and reports a substantial improvement. Other two on the same drug worsened over six weeks.
-
Three clinical trials for Long COVID are testing JAK inhibitors (Jen)
Jen took the JAK inhibitor upadacitinib (Rinvoq) for 66 days starting December 2023 before stopping early due to profound weakness and paralyzing fatigue with no apparent benefit while on the drug. She had suffered from severe myalgic encephalomyelitis for…
-
JAK1 inhibitor Rinvoq quickly returns severely ill ME/CFS patient to health - Parts I and II
Took Rinvoq (upadacitinib) for two months without stating a dose, and describes it as not an easy drug to take. The gains were concentrated in the autonomic nervous system: orthostatic intolerance normalised with no further blood pressure drop or pre-syncope…